A buyout consortium has bid below analyst predictions for the generic drugs unit of Merck following a number of mis-valuations of the healthcare sector in recent weeks.

The group, consisting of Apax Partners and Bain Capital, has offered only just over €4bn ($5.5bn) for the pharmaceuticals company after analysts at Credit Suisse predicted that anything lower than €4.6bn would be surprising.